Literature DB >> 24724911

HLA-DRB1*07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population.

Wilson Baleotti1, Marcelo Ortega Ruiz, Antonio Fabron, Lilian Castilho, Silvana Giuliatti, Eduardo Antonio Donadi.   

Abstract

BACKGROUND: The Diego blood group presents a major polymorphic site at Residue 854, causing a proline (Di(b) antigen) to leucine (Di(a) antigen) substitution. Di(a) alloimmunization has been observed among Asian and Native South American populations. Considering that Brazilians represent a genetically diverse population, and considering that we have observed a high incidence of Di(a) alloimmunization, we typed HLA-DRB1 alleles in these patients and performed in silico studies to investigate the possible associated mechanisms. STUDY DESIGN AND METHODS: We studied 212 alloimmunized patients, of whom 24 presented immunoglobulin G anti-Di(a) , 15 received Di(a+) red blood cells and were not immunized, and 1008 were healthy donors. HLA typing was performed using commercial kits. In silico analyses were performed using the TEPITOPEpan software to identify Diego-derived anchor peptide binding to HLA-DRB1 molecules. Residue alignment was performed using the IMGT/HLA for amino acid identity and homology analyses.
RESULTS: HLA-DRB1*07:01 allele was overrepresented in Di(a) -alloimmunized patients compared to nonimmunized patients and to healthy donors. Two motifs were predicted to be potential epitopes for Di(a) alloimmunization, the WVVKSTLAS motif was predicted to bind several HLA-DR molecules, and the FVLILTVPL motif exhibited highest affinity for the HLA-DRB1*07:01 molecule. Pocket 4 of the DRB1*07:01 molecule contained specific residues not found in other HLA-DRB1 molecules, particularly those at Positions 13(Y), 74(Q), and 78(V).
CONCLUSION: Individuals carrying the HLA-DRB1*07:01 allele present an increased risk for Di(a) alloimmunization. The identification of susceptible individuals and the knowledge of potential sensitization peptides are relevant approaches for transfusion care, diagnostic purposes, and desensitization therapies.
© 2014 AABB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24724911     DOI: 10.1111/trf.12652

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

Review 1.  Transfusion-related red blood cell alloantibodies: induction and consequences.

Authors:  Christopher A Tormey; Jeanne E Hendrickson
Journal:  Blood       Date:  2019-02-26       Impact factor: 22.113

2.  Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice.

Authors:  Seema R Patel; Ashley Bennett; Kathryn Girard-Pierce; Cheryl L Maier; Satheesh Chonat; Connie M Arthur; Patricia E Zerra; Amanda Mener; Sean R Stowell
Journal:  Blood Adv       Date:  2018-01-23

3.  Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Satheesh Chonat; Andreas Wieland; Manjula Santhanakrishnan; Jingchun Liu; Cheryl L Maier; Ryan P Jajosky; Kathryn Girard-Pierce; Ashley Bennett; Patricia E Zerra; Nicole H Smith; Jeanne E Hendrickson; Sean R Stowell
Journal:  JCI Insight       Date:  2018-11-15

Review 4.  Responder individuality in red blood cell alloimmunization.

Authors:  Günther F Körmöczi; Wolfgang R Mayr
Journal:  Transfus Med Hemother       Date:  2014-10-28       Impact factor: 3.747

Review 5.  The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders.

Authors:  Eric A Gehrie; Christopher A Tormey
Journal:  Transfus Med Hemother       Date:  2014-11-17       Impact factor: 3.747

Review 6.  Optimized Antigen-Matched in Sickle Cell Disease Patients: Chances and Challenges in Molecular Times - the Brazilian Way.

Authors:  Lilian Castilho; Carla Luana Dinardo
Journal:  Transfus Med Hemother       Date:  2018-07-06       Impact factor: 3.747

7.  Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Authors:  Seema R Patel; David R Gibb; Kathryn Girard-Pierce; Xiaoxi Zhou; Lilian Cataldi Rodrigues; Connie M Arthur; Ashley L Bennett; Ryan P Jajosky; Megan Fuller; Cheryl L Maier; Patricia E Zerra; Satheesh Chonat; Nicole H Smith; Christopher A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

8.  Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction.

Authors:  Jeanne E Hendrickson
Journal:  Ann Blood       Date:  2020-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.